Overview
| Name | BoltzGen · aliases: BoltzGen |
|---|---|
| Full name | No expanded name; the release page uses BoltzGen only |
| Ambiguous names (not auto-linked) | Boltz |
| Family | Not a family entry. Record covers BoltzGen only; the closed successor BoltzProt-1 is unverified and not merged in |
| Organization | MIT Jameel Clinic, Boltz PBC |
| Organization type | Open-source community |
| Country | United States |
| Model class | Design (co-folding generation: protein / peptide / nanobody) |
| Domain | Proteins (also: Molecule generation, Structure & co-folding) |
| First release | † partly verified · code release Basis: First public code and weights (first repository commit, corroborated by two technology outlets) Note: The site said 2025-11; the manuscript sits on the release page and repository, the bioRxiv entry (2025-11-24) is later source |
| Other milestones |
|
| Latest update | · new version Basis: GitHub release v0.3.2 v0.3.2 fixes binding_types; v0.3.1 (2026-03-06) added per-residue constraints and ipSAE, v0.3.0 (2026-02-10) symmetric inverse folding and covalent bonds; commits continue to 2026-11-01 source The most recent sourced event, not a claim that nothing changed since. |
| Status | Active · Version releases and ongoing commits within 12 months |
| Openness | Code: Open Weights: Open Code and weights both public on GitHub; licence text not retrieved this round, so both terms are left empty |
| Benchmarks reported | 0 counted · none of the 44 |
| Wet-lab validation | 5 recorded campaigns |
| Unverified fields | † wetlab_validation[4], background.funding, background.products_partnerships, first_release, open_status.code_license, open_status.weights_license |
| As of | 2026-11-16 |
What it does
Puts structure prediction and design in one generative framework, generating binders conditioned on protein, peptide or small-molecule targets under design constraints. Shares lineage with Boltz-2 but is not a structure predictor; unlike the backpropagation route of BindCraft it is a trained generative model, and unlike the closed Latent-X/X2 and Chai-2 its weights are open and reproducible.
Benchmarks reported
None of the 44 benchmarks. This model is on the zero-pairing list.
How it evaluates itself: Novel-target wet-lab benchmark; Known-target check; Partner laboratory campaigns; Folding-model parity
Other evaluations (outside the 44)
- Own novel-target wet-lab evaluation (Wet-lab validation) Self-reported: Ten novel targets, two modalities, top 15 designs per modality assayed as the developers' own evaluation set
- Known-target check (Wet-lab validation) Self-reported: Reuses another model's five published easy targets as a control
- Partner laboratory campaigns (Case study) Self-reported: Functional and affinity readouts across campaigns; scale and executor attribution unverified
- Parity with folding models (Comparison against baselines only) Self-reported: The release page claims parity with contemporary folding models and gives no metrics
Developers report: one open model designs protein, nanobody and peptide binders across target types and reaches nanomolar binders on novel targets without known binders.
Independent evidence: No independent evidence found. Wet-lab work was CRO- and partner-executed but compiled by the developers; no independent replication or third-party evaluation found
Training data
Group in Figure 7: Public data + wet lab for validation only.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | PDB, AFDB and similar public structure data (Boltz family) source |
| b. Private or licensed data | No | None for this model; a later pharma collaboration uses that company's historical data, outside this model source |
| c. Own wet-lab data used for training | No | |
| d. Wet lab used only for validation | Yes | Designs assayed in the wet lab, run by a CRO with orthogonal confirmation by a second vendor author-hosted manuscript (link not published) |
Wet-lab validation
Every rate carries its numerator and denominator. Claims that could not be verified are shown as unverified, without numbers; different paper versions are separate entries.
Denominator basis: Ten novel targets with no bound structure in the PDB (1%-27.9% identity to any protein seen bound); 60,000 nanobodies designed per target, top 15 per modality assayed
Denominator follows the manuscript (10), not the release page (9)
Executor: CRO-executed with orthogonal confirmation by a second vendor; not an independent evaluation
Denominator basis: Same ten targets; 60,000 miniproteins designed per target, top 15 assayed
A second 6/9 figure once published had no source and is removed
Executor: CRO-executed with orthogonal confirmation by a second vendor
Denominator basis: Release page states nine novel targets
Kept only as that version's own figure; it disagrees with the manuscript denominator (10) and must never be merged with it
Executor: Developer's own account
Denominator basis: Five easy targets, each present at 100% identity in at least one bound PDB structure
The site's 4/5 holds for nanobodies only
Executor: CRO-executed
Denominator basis: The abstract cites eight design campaigns with functional and affinity readouts across several targets; the manuscript does not describe all of them as external partner-lab work
No figures given: the published 'external labs' framing is unsupported
Executor: Partner laboratories, attribution unverified
Background
- Organization: The model comes from a US university AI-health clinic together with the Boltz team. Boltz PBC, a public benefit corporation, launched 2026-01-08 in Cambridge, Massachusetts; it pairs open research models with closed enterprise models and does not develop therapeutics itself. No public headcount.
- Funding: $28M seed led by Amplify, a16z and Zetta Venture Partners with further funds and angels; a $125M valuation appears only in second-hand reports and is not adopted.
- Products and partnerships: 2026-01-08 multi-year collaboration with a large pharma company (fine-tuning on its historical data, base models stay open, terms undisclosed); 2026-06-18 collaboration with another pharma company granting model and API access, terms undisclosed. The closed successor BoltzProt-1 (2026-06-16) is said to raise hit rates nearly threefold, while a second-hand report says 2.4x; the figures conflict and are unverified.
- Related models: Boltz-1 / Boltz-1x, Boltz-2, BindCraft, Latent-X / Latent-X2, Chai-2
Reading notes
- The same campaign has two denominators (release page nine targets, manuscript ten); read them by version and never merge them into "6/9 in both modalities".
- Rates are per target, not per design: 60,000 designs per target, only the top 15 assayed.
- Wet-lab work was CRO- and partner-executed and developer-compiled, so it is not independent replication; the "26 external labs" framing has no source.
- No site benchmark entry exists, so comparability rests on the wet lab and on the same easy-target set used by Chai-2.
Caveats
- Zero pairings: the manuscript reports no site benchmark.
- Release page and manuscript disagree on target and hit counts; listed per version.
- Partner campaign target counts and success rates are not given as numbers (unverified).
- The successor BoltzProt-1 is closed and its claimed gain is reported two conflicting ways.
Sources
- author-hosted manuscript (link not published) (preprint)
- BoltzGen preprint record (preprint)
- Research-institute release page (official site)
- GitHub releases (repository)
- BoltzProt-1 note reposted by a third-party platform (second-hand) (second-hand) second-hand
Corrections
5 corrections
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| wetlab_validation | 6/9 for both modalities | Manuscript: nanobody 6/10, miniprotein 5/10; the release page separately records 6/9 (nanobody); listed separately by version | author-hosted manuscript (link not published) | 2026-11-16 |
| wetlab_validation | Easy targets 4/5 | Nanobody 4/5, miniprotein 3/5 | author-hosted manuscript (link not published) | 2026-11-16 |
| wetlab_validation | 26 targets validated by 26 external labs | No number given: the manuscript does not say "external labs"; a CRO ran the work | author-hosted manuscript (link not published) | 2026-11-16 |
| release_milestones.paper_v1 | No bioRxiv entry | bioRxiv v1 exists (2025-11-24), not published in a journal | source | 2026-11-16 |
| first_release | 2025-11 | 2025-10-26 (code and weights public) | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.